Company
BELLUS Health Inc.
Headquarters: Laval, QC, Canada
Employees: 40
CEO: Mr. Roberto Francesco Bellini
Market Cap
C$2.47 Billion
CAD as of June 1, 2023
US$1.86 Billion
BELLUS Health Inc. Categories
Canada Healthcare BiotechnologyCanada Healthcare Canada Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Financials
| Last Financial Reports Date | March 31, 2023 |
| Revenue TTM | C$16,000 |
| EBITDA | C$0 |
| Gross Profit TTM | C$0 |
| Profit Margin | % |
| Operating Margin | -474637.50% |
| Quarterly Revenue Growth | -25.00% |
Stocks & Indices
BELLUS Health Inc. has the following listings and related stock indices.
Stock: TSX: BLU wb_incandescent
Stock: NASDAQ: BLU wb_incandescent
Stock: FSX: BHN0 wb_incandescent